Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
229.5 SEK | -4.38% | +4.32% | +8.25% |
Feb. 07 | Transcript : CellaVision AB, Q4 2023 Earnings Call, Feb 07, 2024 | |
Feb. 07 | CellaVision AB Proposes Dividend for the Year 2023 | CI |
Sales 2024 * | 779M 71.73M | Sales 2025 * | 889M 81.81M | Capitalization | 5.72B 527M |
---|---|---|---|---|---|
Net income 2024 * | 174M 16.01M | Net income 2025 * | 218M 20.06M | EV / Sales 2024 * | 7.19 x |
Net cash position 2024 * | 117M 10.76M | Net cash position 2025 * | 208M 19.16M | EV / Sales 2025 * | 6.2 x |
P/E ratio 2024 * |
33
x | P/E ratio 2025 * |
26.2
x | Employees | - |
Yield 2024 * |
1.03% | Yield 2025 * |
1.15% | Free-Float | 61.96% |
Latest transcript on CellaVision AB
1 day | +0.42% | ||
1 week | +9.84% | ||
Current month | +0.42% | ||
1 month | +10.09% | ||
3 months | +29.59% | ||
6 months | +71.43% | ||
Current year | +13.21% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 94-11-15 | |
Simon Ostergaard
CEO | Chief Executive Officer | 53 | 21-03-20 |
Magnus Blixt
DFI | Director of Finance/CFO | 58 | 13-05-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 59 | 94-11-15 | |
Lotta Jarleryd
BRD | Director/Board Member | 58 | 22-05-10 |
Mikael Worning
CHM | Chairman | 62 | 20-04-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 229.5 | -4.38% | 186 213 |
24-04-24 | 240 | +0.42% | 24,951 |
24-04-23 | 239 | +2.58% | 13,308 |
24-04-22 | 233 | +3.79% | 43,188 |
24-04-19 | 224.5 | +2.05% | 6,409 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.21% | 526M | |
-12.06% | 19.18B | |
-44.61% | 2.73B | |
+16.10% | 1.84B | |
-3.24% | 1.61B | |
+20.19% | 1.18B | |
-21.52% | 898M | |
-8.03% | 710M | |
-16.68% | 694M | |
-.--% | 301M |
- Stock Market
- Equities
- CEVI Stock